Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 231-237

  Bylicki, O ^a,b   Gan, H K ^c   Joly, F ^d,e,f   Maillet, D ^g   You, B ^b,g,h   Péron, Julien ^g,i,j  

^a Desgenettes Hospital   (France)

^b UNIVERSITÉ DE LYON   (France)

^c AUSTIN HOSPITAL   (Australia)

^d Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers'   (France)

^e Cancer Institute   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

more..

Author keywords

Patients reported outcomes; Quality of life; Randomized clinical trials; Reporting quality

Indexed keywords

ARTICLE; CANCER THERAPY; DATA PROCESSING; HUMAN; INFORMATION PROCESSING; METHODOLOGY; ONCOLOGY; PATIENT-REPORTED OUTCOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; SYSTEMIC THERAPY; NEOPLASMS; OUTCOME ASSESSMENT; QUALITY OF LIFE; SELF REPORT; STANDARDS;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SELF REPORT;

EID: 84969405461     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/ANNONC/MDU489     Document Type: Article

References (17)

1. US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009; http://www.fda.gov/cder/guidance/index.htm (28 July 2014, date last accessed)
2. Niraula S, Seruga B, Ocana A et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012; 30: 3012-3019
3. Lipscomb J, Reeve BB, Clauser SB et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 2007; 25: 5133-5140
4. Gnanasakthy A, Mordin M, Clark M et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 2012; 15: 437-442
5. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865-869
6. Johnston BC, Patrick DL, Busse JW et al. Patient-reported outcomes in metaanalyses-part 1: assessing risk of bias and combining outcomes. Health Qual Life Outcomes 2013; 11: 109
7. Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and opportunities. Qual Life Res 2009; 18(1): 99-107
8. Alemayehu D, Cappelleri JC. Conceptual and analytical considerations toward the use of patient-reported outcomes in personalized medicine. Am Heal Drug Benefits 2012; 5(5): 310-317
9. Efficace F, Osoba D, Gotay C et al. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007; 18: 775-781
10. Calvert M, Brundage M, Jacobsen PB et al. The CONSORT patient-reported outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 2013; 11: 184
11. Brundage M, Bass B, Davidson J et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res 2011; 20: 653-664
12. Calvert M, Blazeby J, Altman DG et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013; 309: 814-822
13. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332
14. Péron J, Maillet D, Gan HK et al. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol 2013; 31: 3957-3963
15. Péron J, Pond GR, Gan HK et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst 2012; 104: 982-989
16. US Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. 2007; http://www.fda. gov/cder/guidance/index.htm (28 July 2014, date last accessed)
17. Easterbrook PJ, Berlin JA, Gopalan R et al. Publication bias in clinical research. Lancet 1991; 337: 867-872